Botulinum toxin for chronic migraine: Clinical trials and technical aspects

Cristina Tassorelli, Grazia Sances, Micol Avenali, Roberto De Icco, Daniele Martinelli, Vito Bitetto, Giuseppe Nappi, Giorgio Sandrini

Research output: Contribution to journalArticle

Abstract

OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.

Original languageEnglish
JournalToxicon
DOIs
Publication statusE-pub ahead of print - Sep 4 2017

Fingerprint

Information Management
Botulinum Toxins
Migraine Disorders
Demonstrations
Clinical Trials
onabotulinumtoxinA

Keywords

  • Journal Article

Cite this

Botulinum toxin for chronic migraine : Clinical trials and technical aspects. / Tassorelli, Cristina; Sances, Grazia; Avenali, Micol; De Icco, Roberto; Martinelli, Daniele; Bitetto, Vito; Nappi, Giuseppe; Sandrini, Giorgio.

In: Toxicon, 04.09.2017.

Research output: Contribution to journalArticle

Tassorelli, Cristina ; Sances, Grazia ; Avenali, Micol ; De Icco, Roberto ; Martinelli, Daniele ; Bitetto, Vito ; Nappi, Giuseppe ; Sandrini, Giorgio. / Botulinum toxin for chronic migraine : Clinical trials and technical aspects. In: Toxicon. 2017.
@article{a3506244d4294c03a470fce7dc22361a,
title = "Botulinum toxin for chronic migraine: Clinical trials and technical aspects",
abstract = "OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.",
keywords = "Journal Article",
author = "Cristina Tassorelli and Grazia Sances and Micol Avenali and {De Icco}, Roberto and Daniele Martinelli and Vito Bitetto and Giuseppe Nappi and Giorgio Sandrini",
note = "Copyright {\circledC} 2017 Elsevier Ltd. All rights reserved.",
year = "2017",
month = "9",
day = "4",
doi = "10.1016/j.toxicon.2017.08.026",
language = "English",
journal = "Toxicon",
issn = "0041-0101",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Botulinum toxin for chronic migraine

T2 - Clinical trials and technical aspects

AU - Tassorelli, Cristina

AU - Sances, Grazia

AU - Avenali, Micol

AU - De Icco, Roberto

AU - Martinelli, Daniele

AU - Bitetto, Vito

AU - Nappi, Giuseppe

AU - Sandrini, Giorgio

N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.

PY - 2017/9/4

Y1 - 2017/9/4

N2 - OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.

AB - OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.

KW - Journal Article

U2 - 10.1016/j.toxicon.2017.08.026

DO - 10.1016/j.toxicon.2017.08.026

M3 - Article

C2 - 28877509

JO - Toxicon

JF - Toxicon

SN - 0041-0101

ER -